Non-Small Cell Lung Cancer (NSCLC)- Metastatic

Recurrent or Metastatic (IIIB, IV)

1st line

Squamous

- IRB# 19330
  A Phase 3, randomized, double-blind trial of pembrolizumab with or without lenvatinib in participants with treatment-naïve, metastatic NSCLC whose tumors have a tumor proportion score greater than or equal to 1%

Non-squamous

- IRB# 19351
  A Phase 3 Randomized, Placebo-controlled Study to Evaluate Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab with or without Lenvatinib in Participants with Metastatic Nonsquamous NSCLC

- IRB# 19330
  A Phase 3, randomized, double-blind trial of pembrolizumab with or without lenvatinib in participants with treatment-naïve, metastatic NSCLC whose tumors have a tumor proportion score greater than or equal to 1%

- IRB# 20077
  A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

- IRB# 19992
  EAY131 (MATCH)

- IRB# TBD
  S1609 (DART)

2nd/3rd Line

- IRB# 20194
  Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-Small Cell Lung Cancer or Urothelial Cancer

- IRB# 19566
  A Phase II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETEROUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NSCLC (LUNG-MAP SUB-STUDY)

Please contact Matt Crocker at crockerm@ohsu.edu or 503-418-9389 with questions.

http://www.ohsu.edu/research/rda/so/knight.php